Abstract:e15078 Background: Immune checkpoint blockades (ICBs) have been approved for colorectal cancer (CRC) with microsatellite instability high (MSI-H). However, 50% to 60% MSI-H and almost 100% microsatellite stability (MSS) CRC patients can’t benefit from ICBs treatment. How to warm these “cold tumor” for boosting response to ICBs is still a problem. We aimed to integrate the expression signatures of T cell activation, exclusion and dysfunction to generate immune microenvironment subtypes which may guide precision immunotherapy. Methods: RNA-Seq of 596 CRC patients from The Cancer Genome Atlas were analyzed. T cell activation, dysfunction and exclusion signatures were calculated from TIDE model algorithm. Unsupervised clustering was used to classify CRC into various immune subtypes. Mann Whitney U test and Kruskal test were used to compare the difference among two or more than two groups. COX regression multivariate analysis was applied to analyze the association of subtypes with overall survival (OS). Results: Compared with 543 patients with MSS, 83 patients had significantly higher expression of T cell activation related genes (including CD8A, CXCL9, CXCL10, GZMB, IFNG et al) and immune checkpoint genes (including PD-L1, PD-1, LAG3 et al.), but lower signatures scores of M2-like tumor-associated macrophage (TAM) and T cell exclusion ( all P value<0.001). Based on expression signatures of myeloid-derived suppressor cell (MDSC), cancer-associated fibroblast (CAF), M2-like TAM, cytotoxic T-lymphocytes (CTL) and PD-L1, all the patients were clustered into four subtypes. Cluster 4 was enriched by MSI-H and characterized with high T cell activation and moderate T cell dysfunction and exclusion. Comparatively, another MSI-H enriched Cluster 1 had both high CTL and T cell dysfunction which indicated that activated T cell might be escaped by tumor cell. Cluster 2 and Cluster 3 were enriched by MSS and characterized with moderate T cell activation and high T cell exclusion. In survival analysis, Cluster 4 had prolonged OS (HR [95% CI]=0.46 [0.27-0.80]) compared with Cluster 1, 2 and 3, after adjusted for age, pathological stage, tumor residue, MSI status, BRAF and PIK3CA mutations. In MSS, Cluster 4 also had better prognosis than the other three clusters (HR [95% CI]=0.38 [0.20-0.73]). Conclusions: Our findings provide evidence to guide further patient stratification in ICBs treatment. The distinct immune subtypes of CRC also paved the way of combination immunotherapy based on immune microenviroment to turn “cold tumor” into “hot tumor”.

Assessment of renal perfusion: advocacy for Doppler ultrasonography.

Anticoagulants in the treatment of renal disease.

Definition of immune molecular subtypes with distinct immune microenvironment, recurrence, and PANoptosis features to aid clinical therapeutic decision-making

Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy

Identification of a Novel Immune-Related Prognostic Model for Patients with Colorectal Cancer Based on 3 Subtypes.

Regulation of neuron survival and death by p130 and associated chromatin modifiers.

Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy

Multi-dimensional characterization of immunological profiles in small cell lung cancer uncovers clinically relevant immune subtypes with distinct prognoses and therapeutic vulnerabilities

Identification of an immune classification for cervical cancer and integrative analysis of multiomics data

Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy

Analysis of Immune-Related Signatures of Colorectal Cancer Identifying Two Different Immune Phenotypes: Evidence for Immune Checkpoint Inhibitor Therapy.

Prognosis and immunotherapeutic implications of molecular classification of cervical cancer based on immunophenoscore-related genes

Identification of Immune Subtypes to Guide Immunotherapy and Targeted Therapy in Clear Cell Renal Cell Carcinoma

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy

Exploration of Immunogenic Cell Death-Associated Genes for Predicting Prognosis and Immunological Characteristics in Cervical Squamous Cell Carcinoma

Subtyping of head and neck squamous cell cancers based on immune signatures

Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors.

Comprehensive Immune Transcriptomic Subtypes of Colorectal Cancer for Development of Precision Immunotherapy.

Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis

Immune-related lncRNA classification of head and neck squamous cell carcinoma

Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity